With only a small number of approved regenerative therapies on the market and many clinical trials currently being completed on a small scale, the opportunities to learn from completed clinical trials are slim.
However with larger clinical investigations currently underway in pharma and biotechs, there is an opportunity to learn from their successes and failures to adopt industry best practice.
REGEN 2013 explored the pioneering clinical trials in the field in order to provide guidance on the design and execution of your own clinical trial.
The meeting help attendees to understand the clinical strategies for some of the most promising regenerative medicines and enabled you to optimize your practices and push your therapy through to patients faster.
Designed to give you access to the acquired knowledge and experience of the industry, REGEN 2013 provided a unique opportunity for you to identify common flaws in clinical trial designs in order to design the most effective clinical strategy for your product.
Attending the meeting meant understanding what investors really need to see to validate investment. Attendees found out how you can demonstrate cost effectiveness to the satisfaction of payors and ultimately achieve reimbursement for your product.
REGEN 2013: Clinical Trials & Reimbursement - the only meeting dedicated to providing you with the practical guidance and advice you need to perfect your clinical trial structure. If you are working in clinical development or looking to enter the clinic with your cell based regenerative product then this meeting addressed the major challenges you need to overcome to reach the market.
This means the meeting was for:
Learn from the experience of your peers and make sure you have the knowledge you need to ensure your clinical trial is optimal for proving safety and efficacy for your cell based regenerative medicine.
Download the brochure to see what will be covered at the meeting
Don't forget to check out the Interactive Pre-Conference Workshops
Choose your package - see prices and discounts here (with significant discounts for non-profit institutions)
“Great breadth and depth with all stakeholders represented” AstraZeneca
“Well organised. Far easier to network than at other events. Great job!” Biogen Idec
“Excellent conference” Merck & Co
“Very valuable, well organized, good diversity of speakers” Daiichi-Sankyo